Javascript must be enabled to continue!
Non-canonical cell death by reassortant reovirus
View through CrossRef
Abstract
Triple-negative breast cancer (TNBC) constitutes 12% of all breast cancer and is associated with worse prognosis compared to other subtypes of breast cancer. Current therapies are limited to cytotoxic chemotherapy, radiation, and surgery, leaving a need for targeted therapeutics to improve outcomes for TNBC patients. Mammalian orthoreovirus (reovirus) is a nonenveloped, segmented, dsRNA virus in the
Reoviridae
family. Reovirus preferentially kills transformed cells and is in clinical trials to assess its efficacy against several types of cancer. We previously engineered a reassortant reovirus, r2Reovirus, that infects TNBC cells more efficiently and induces cell death with faster kinetics than parental reoviruses. In this study, we sought to understand the mechanisms by which r2Reovirus induces cell death in TNBC cells. We show that r2Reovirus infection of TNBC cells of a mesenchymal-stem like (MSL) lineage downregulates the MAPK/ERK pathway and induces non-conventional cell death that is caspase dependent, but caspase 3-independent. Infection of different MSL lineage TNBC cells with r2Reovirus results in caspase 3-dependent cell death. We map the enhanced oncolytic properties of r2Reovirus in TNBC to epistatic interactions between the Type 3 Dearing M2 gene segment and Type 1 Lang genes. These findings suggest that the genetic composition of the host cell impacts the mechanism of reovirus-induced cell death in TNBC. Together, our data show that understanding host and virus determinants of cell death can identify novel properties and interactions between host and viral gene products that can be exploited for the development of improved viral oncolytics.
Importance
Triple negative breast cancer (TNBC) is unresponsive to hormone therapies, leaving patients afflicted with this disease with limited treatment options. We previously engineered an oncolytic reovirus (r2Reovirus) with enhanced infective and cytotoxic properties in TNBC cells. However, how r2Reovirus promotes TNBC cell death is not known. In this study, we show that reassortant r2Reovirus can promote non-conventional caspase-dependent but caspase 3-independent cell death and that the mechanism of cell death depends on the genetic composition of the host cell. We also map the enhanced oncolytic properties of r2Reovirus in TNBC to interactions between a Type 3 M2 gene segment and Type 1 genes. Our data show that understanding the interplay between the host cell environment and the genetic composition of oncolytic viruses is crucial for the development of efficacious viral oncolytics.
Title: Non-canonical cell death by reassortant reovirus
Description:
Abstract
Triple-negative breast cancer (TNBC) constitutes 12% of all breast cancer and is associated with worse prognosis compared to other subtypes of breast cancer.
Current therapies are limited to cytotoxic chemotherapy, radiation, and surgery, leaving a need for targeted therapeutics to improve outcomes for TNBC patients.
Mammalian orthoreovirus (reovirus) is a nonenveloped, segmented, dsRNA virus in the
Reoviridae
family.
Reovirus preferentially kills transformed cells and is in clinical trials to assess its efficacy against several types of cancer.
We previously engineered a reassortant reovirus, r2Reovirus, that infects TNBC cells more efficiently and induces cell death with faster kinetics than parental reoviruses.
In this study, we sought to understand the mechanisms by which r2Reovirus induces cell death in TNBC cells.
We show that r2Reovirus infection of TNBC cells of a mesenchymal-stem like (MSL) lineage downregulates the MAPK/ERK pathway and induces non-conventional cell death that is caspase dependent, but caspase 3-independent.
Infection of different MSL lineage TNBC cells with r2Reovirus results in caspase 3-dependent cell death.
We map the enhanced oncolytic properties of r2Reovirus in TNBC to epistatic interactions between the Type 3 Dearing M2 gene segment and Type 1 Lang genes.
These findings suggest that the genetic composition of the host cell impacts the mechanism of reovirus-induced cell death in TNBC.
Together, our data show that understanding host and virus determinants of cell death can identify novel properties and interactions between host and viral gene products that can be exploited for the development of improved viral oncolytics.
Importance
Triple negative breast cancer (TNBC) is unresponsive to hormone therapies, leaving patients afflicted with this disease with limited treatment options.
We previously engineered an oncolytic reovirus (r2Reovirus) with enhanced infective and cytotoxic properties in TNBC cells.
However, how r2Reovirus promotes TNBC cell death is not known.
In this study, we show that reassortant r2Reovirus can promote non-conventional caspase-dependent but caspase 3-independent cell death and that the mechanism of cell death depends on the genetic composition of the host cell.
We also map the enhanced oncolytic properties of r2Reovirus in TNBC to interactions between a Type 3 M2 gene segment and Type 1 genes.
Our data show that understanding the interplay between the host cell environment and the genetic composition of oncolytic viruses is crucial for the development of efficacious viral oncolytics.
Related Results
Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy
Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy
Background
Many solid tumors do not respond to immunotherapy due to their immunologically cold tumor microenvironment (TME). We and others found that oncolytic vi...
Abstract 1779: Selective oncolysis of multiple myeloma cells by reovirus is mediated through apoptosis
Abstract 1779: Selective oncolysis of multiple myeloma cells by reovirus is mediated through apoptosis
Abstract
Introduction: Multiple myeloma (MM) is an incurable hematologic malignancy that accounts for 10% of hematopoietic neoplasms. Recently we have demonstrated t...
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
Background
T-cell-engaging CD3-bispecific antibodies (CD3-bsAbs) are promising modalities for cancer immunotherapy. Although this therapy has reached clinical pra...
Baculovirus-assisted Reovirus Infection in Monolayer and Spheroid Cultures of Glioma cells
Baculovirus-assisted Reovirus Infection in Monolayer and Spheroid Cultures of Glioma cells
AbstractThe mammalian orthoreovirus Type 3 Dearing has great potential as oncolytic agent in cancer therapy. One of the bottlenecks that hampers its antitumour efficacy in vivo is ...
Abstract 591: Reovirus is oncolytic towards organ specific and highly metastatic lung cancer cells: Possible mechanisms of action.
Abstract 591: Reovirus is oncolytic towards organ specific and highly metastatic lung cancer cells: Possible mechanisms of action.
Abstract
Introduction: Metastasis from lung adenocarcinoma can occur rapidly to multiple organs within months of diagnosis. Despite early diagnosis and surgical remo...
Oncolytic Reovirus Infection Is Facilitated by the Autophagic Machinery
Oncolytic Reovirus Infection Is Facilitated by the Autophagic Machinery
Mammalian reovirus is a double-stranded RNA virus that selectively infects and lyses transformed cells, making it an attractive oncolytic agent. Despite clinical evidence for anti-...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Data from Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma
Data from Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma
<div>Abstract<p><b>Purpose:</b> Despite the recent advances made in the treatment of multiple myeloma, the disease still remains incurable. The oncolytic po...

